TIDES IN INDIAN PHARMA

TIDES IN INDIAN PHARMA

By Levin Thomas

SUN PHARMA SET TO BUY RANBAXY LABORATARIES

Sun Pharmaceutical Industries has agreed to buy generic drug maker Ranbaxy Laboratories Ltd. for $ 3.2 billion from its current Japanese owner Daiichi Sankyo.  The all stock transaction, historically the largest domestic deal by size in the Indian pharmaceutical sector will create the world’s fifth largest maker of generic drugs. The deal is expected to close by the end of this year. Post the completion of transaction, it will run as a single company. The deal comes against the backdrop of a slew of sanctions against Ranbaxy by US FDA due to concerns about manufacturing processes at its Indian plants. Sun Pharma’s strong sales base in the US, along with its supply chain management that has been strong enough to meet FDA standards in most cases and a good record in managing troubled acquisitions, made the company an attractive buyer for Daiichi Sankyo. Under terms of agreed deal, Ranbaxy share holders will get 0.8 Sun Pharma shares for each Ranbaxy share they own.

“Shan5”: READY FOR MARKETING

The pediatric pentavalent vaccine “Shan5” of Sanofi Pasteur, developed and manufactured by its affiliate Shantha Biotechnics, has received prequalification status from WHO and approval from DCGI to market the vaccine in India. The combination vaccine offers protection to children from diphtheria, tetanus, pertussis, Hib and hepatitis B. The three dose vaccine can be given starting from 6 weeks with a gap of 4 weeks up to 14 weeks of age. 

Sl No.	Drugs	Indication
1	Azacitidine 100mg/vial (Injection)	Treatment of adult patients with subtypes of Myelodysplastic Syndrome
2	Tulobuterol 0.5mg/1.0mg/2.0mg (Transdermal Patch)	Treatment of adult patients with Asthma & COPD
3	Pegaspargase 3750 IU/5ml (Injection)	Treatment of patients with Acute lymphoblastic leukemia who are hypersensitive to Asparaginase
4	Tolterodine tartrate 2mg/4mg (Extended release tablets)	Treatment of Overactive bladder
5	Bortezomib 3.5mg (Sub-cutaneous)	Treatment of Multiple Myeloma
6	Paclitaxel 100mg/300mg (Injection concentrate for nanodispersion)	Treatment of Breast cancer
7	Heparin sodium 1000IU/ml (Topical solution)	Management of post infusion superficial thrombophlebitis